KLH-2109: Phase IIb started

ObsEva began the double-blind, placebo-controlled, international Phase IIb EDELWEISS trial to evaluate 5 dose levels of oral OBE2109 once daily for 24 weeks in about 330 patients with pelvic pain asso...